Ruiyi Zhu
Shijiazhuang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Corrigendum to "A metabonomics-based renoprotective mechanism analysis of empagliflozin in obese mice" [Biochem. Biophys. Res. Commun. 621 (2022) 122-129].
Journal: Biochemical and biophysical research communications
Published: September 04, 2025
Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice.
Journal: Frontiers in endocrinology
Published: November 11, 2022
Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice.
Journal: Drug design, development and therapy
Published: July 23, 2022
Single-cell transcriptome reveals effects of semaglutide on non-cardiomyocytes of obese mice.
Journal: Biochemical and biophysical research communications
Published: July 04, 2022
Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice.
Journal: Frontiers in pharmacology
Published: June 22, 2022
Effect of high-fat diet and empagliflozin on cardiac proteins in mice.
Journal: Nutrition & metabolism
Published: June 15, 2022
A metabonomics-based renoprotective mechanism analysis of empagliflozin in obese mice.
Journal: Biochemical and biophysical research communications
Published: June 09, 2022
Single-cell transcriptomics identifies Col1a1 and Col1a2 as hub genes in obesity-induced cardiac fibrosis.
Journal: Biochemical and biophysical research communications
Published: May 22, 2022
UTP14A, DKC1, DDX10, PinX1, and ESF1 Modulate Cardiac Angiogenesis Leading to Obesity-Induced Cardiac Injury.
Journal: Journal of diabetes research
Published: January 09, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026